




Searching News Database: Teva Neuroscience
HSMN NewsFeed - 4 Jun 2010
Teva Announces Positive Results from a Study Assessing a New Formulation of Copaxone(R)
Teva Announces Positive Results from a Study Assessing a New Formulation of Copaxone(R)
HSMN NewsFeed - 25 Feb 2010
Copaxone(R) 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety
Copaxone(R) 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety
HSMN NewsFeed - 10 Sep 2009
COPAXONE(R) Significantly Reduced Disease Severity in Long-Term Treated Multiple Sclerosis Patients
COPAXONE(R) Significantly Reduced Disease Severity in Long-Term Treated Multiple Sclerosis Patients
HSMN NewsFeed - 28 Apr 2009
Long-Term Study with COPAXONE Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
Long-Term Study with COPAXONE Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
HSMN NewsFeed - 18 Sep 2008
Longest Prospective Study in MS Confirmed Robust Clinical Benefits and Safety of COPAXONE(R)
Longest Prospective Study in MS Confirmed Robust Clinical Benefits and Safety of COPAXONE(R)
HSMN NewsFeed - 8 Aug 2007
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
HSMN NewsFeed - 6 Jun 2007
COPAXONE(R) Pre-Filled Syringe Can Now Be Stored for up to One Month at Room Temperature
COPAXONE(R) Pre-Filled Syringe Can Now Be Stored for up to One Month at Room Temperature
HSMN NewsFeed - 22 Dec 2006
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
HSMN NewsFeed - 2 Oct 2006
COPAXONE(R) Showed Sustained Benefit on Slowing Brain Tissue Damage in Multiple Sclerosis Patients
COPAXONE(R) Showed Sustained Benefit on Slowing Brain Tissue Damage in Multiple Sclerosis Patients
HSMN NewsFeed - 12 Jul 2006
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
HSMN NewsFeed - 17 May 2006
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
HSMN NewsFeed - 17 May 2006
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
Additional items found! 27

Members Archive contains
27 additional stories matching:
Teva Neuroscience
(Password required)
Teva Neuroscience
(Password required)